Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications
Laura Goracci, Jenny Desantis, Aurora Valeri, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 20, pp. 11615-11638
Open Access | Times Cited: 109

Showing 1-25 of 109 citing articles:

Advancing targeted protein degradation for cancer therapy
Brandon Dale, Meng Cheng, Kwang‐Su Park, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 10, pp. 638-654
Open Access | Times Cited: 433
PROTACs: past, present and future
Ke Li, Craig M. Crews
Chemical Society Reviews (2022) Vol. 51, Iss. 12, pp. 5214-5236
Open Access | Times Cited: 425
Protein degraders enter the clinic — a new approach to cancer therapy
Deborah Chirnomas, Keith R. Hornberger, Craig M. Crews
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 4, pp. 265-278
Closed Access | Times Cited: 335
Antibody targeting of E3 ubiquitin ligases for receptor degradation
Hadir Marei, Wen‐Ting K. Tsai, Yee-Seir Kee, et al.
Nature (2022) Vol. 610, Iss. 7930, pp. 182-189
Open Access | Times Cited: 159
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Zhenyi Hu, Craig M. Crews
ChemBioChem (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 158
Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders
Claudia J. Diehl, Alessio Ciulli
Chemical Society Reviews (2022) Vol. 51, Iss. 19, pp. 8216-8257
Open Access | Times Cited: 124
E3 ligase ligand chemistries: from building blocks to protein degraders
Izidor Sosič, Aleša Bricelj, Christian Steinebach
Chemical Society Reviews (2022) Vol. 51, Iss. 9, pp. 3487-3534
Closed Access | Times Cited: 92
Accelerated rational PROTAC design via deep learning and molecular simulations
Shuangjia Zheng, Youhai Tan, Zhenyu Wang, et al.
Nature Machine Intelligence (2022) Vol. 4, Iss. 9, pp. 739-748
Closed Access | Times Cited: 78
Rational Design, Synthesis, and Biological Evaluation of Novel c-Met Degraders for Lung Cancer Therapy
Xingyang Qiu, Qingquan Zheng, Dongdong Luo, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 2
Developments of CRBN-based PROTACs as potential therapeutic agents
Chao Wang, Yujing Zhang, Yudong Wu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113749-113749
Closed Access | Times Cited: 96
The rise and rise of protein degradation: Opportunities and challenges ahead
Scott J. Hughes, Andrea Testa, Nicola Thompson, et al.
Drug Discovery Today (2021) Vol. 26, Iss. 12, pp. 2889-2897
Open Access | Times Cited: 59
Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review
Jia Zheng, Wei Zhang, Linfeng Li, et al.
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 51
Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC)
Jiranan Chotitumnavee, Yasunobu Yamashita, Yukari Takahashi, et al.
Chemical Communications (2022) Vol. 58, Iss. 29, pp. 4635-4638
Closed Access | Times Cited: 40
Small-Molecule Hydrophobic Tagging: A Promising Strategy of Druglike Technology for Targeted Protein Degradation
Shaowen Xie, Jingjie Zhu, Junda Li, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 10917-10933
Closed Access | Times Cited: 39
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs
Nikol A. Zografou-Barredo, Alex J. Hallatt, J. S. JUN. RICCI, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 88-89, pp. 117334-117334
Open Access | Times Cited: 34
Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders
Laurie P. Volak, Heide Marika Duevel, Sara C. Humphreys, et al.
Drug Metabolism and Disposition (2023) Vol. 51, Iss. 7, pp. 792-803
Closed Access | Times Cited: 32
The rise of degrader drugs
Mingxing Teng, Nathanael S. Gray
Cell chemical biology (2023) Vol. 30, Iss. 8, pp. 864-878
Open Access | Times Cited: 28
Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
Barmak Mostofian, Holli‐Joi Martin, Asghar M. Razavi, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 17, pp. 5408-5432
Open Access | Times Cited: 28
Application and challenges of nitrogen heterocycles in PROTAC linker
Yang Li, Junfeng Qu, Lizhi Jiang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 273, pp. 116520-116520
Closed Access | Times Cited: 13
Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity
Jenny Desantis, Alessandro Bazzacco, Michela Eleuteri, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116202-116202
Open Access | Times Cited: 11
Towards the Targeted Protein Degradation of PRMT1
Poppy L. Martin, F. Javier Pérez-Areales, Shalini V. Rao, et al.
ChemMedChem (2024) Vol. 19, Iss. 16
Open Access | Times Cited: 9
Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC
Thomas G. Hayhow, Beth Williamson, Mandy Lawson, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 9
Prediction of Proteolysis-Targeting Chimeras Retention Time Using XGBoost Model Incorporated with Chromatographic Conditions
Xinhao Qu, Chen Jiang, Mengyi Shan, et al.
Journal of Chemical Information and Modeling (2025)
Closed Access | Times Cited: 1
Kidney Targeting Smart Antibiotic Discovery: Multimechanism Pleuromutilins for Pyelonephritis Therapy
Lei Tian, Taotao Qiang, Juan Xia, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top